MAPK1 and skin cancer: In skin cancer, in addition to one significant hit after FDR correction, BRAF-specific SL partners including AKT3, KIT, LDLR, and MAPK1 found support in the PRISM dataset (significance level α = 0.1) and in the literature (Supplementary Data 2, 3).